3-(2-氧代丙基)苯甲腈 | 73013-50-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2-氧代丙基)苯甲腈
• 中文别名: 3-(2-氧代丙基)苯腈
• 英文名称: 3-(2-oxopropyl)benzonitrile
• CAS: 73013-50-0
• 化学式: C₁₀H₉NO
• mdl: MFCD03410447
• 分子量: 159.188
• InChiKey: XECXKMQLEFHQHM-UHFFFAOYSA-N

物化性质

• 沸点：
  116 °C(Press: 0.5 Torr)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  3-(2-氧代丙基)苯甲腈 在 吡啶 、 4-二甲氨基吡啶 、 盐酸羟胺 、 sodium acetate 作用下， 以 甲醇 为溶剂， 生成 3-(2-(acetoxyimino)propyl)benzonitrile
  参考文献：
  名称：

  Copper‐Catalyzed Aza‐Sonogashira Cross‐Coupling To Form Ynimines: Development and Application to the Synthesis of Heterocycles

  摘要：

  AbstractNitrogen‐substituted alkynes, such as ynamines and ynamides, are versatile synthetic building blocks. Ynimines bearing additional nucleophilic and electrophilic centers relative to ynamines and ynamides are expected to have high synthetic potential. However, their chemical reactivity remains unexplored owing mainly to the lack of synthetic accessibility. We report herein a versatile copper‐catalyzed synthesis of ynimines from readily available O‐acetyl ketoximes and terminal alkynes. A wide range of O‐acetyl ketoximes derived from diaryl ketones, aryl alkyl ketones and dialkyl ketones underwent cross‐coupling with a diverse set of terminal alkynes to afford the ynimines in good to excellent yields. An unprecedented [5+1] heteroannulation reaction exploiting the reactivity of the ynimine generated in situ was subsequently developed for the synthesis of medicinally important heterocycles, including isoquinolines, azaindoles, azabenzofurans, azabenzothiophenes and carbolines.

  DOI：

  10.1002/anie.202110901
• 作为产物：
  描述：

  3-氰基苯甲醛 在 水 、 三氯化铁 、 铁粉 、 正丁胺 作用下， 以 甲苯 为溶剂， 生成 3-(2-氧代丙基)苯甲腈
  参考文献：
  名称：

  Gardrat, C., Bulletin des Societes Chimiques Belges, 1984, vol. 93, # 10, p. 897 - 902

  摘要：

  DOI：

文献信息

• Photoinduced Cross-Coupling of Aryl Iodides with Alkenes
  作者：Yuliang Liu、Haoyu Li、Shunsuke Chiba

  DOI：10.1021/acs.orglett.0c03935

  日期：2021.1.15

  A protocol for photoinduced cross-coupling of aryl iodides having polar π-functional groups or elongated π-conjugation with alkenes has been developed. The radical cascade mechanism involving generation of aryl radicals via C–I bond homolysis of photoexcited aryl iodides and their subsequent addition to alkenes is proposed. The method enables iodide-selective cross-coupling over other halogen leaving

  已经开发出用于光诱导的具有极性π-官能团的芳基碘的交叉偶联或延长的与烯烃的π-共轭的方案。提出了一种自由基级联机制，涉及通过光激发的芳基碘化物的C–I键均质化及其随后添加到烯烃中的芳基自由基的产生。该方法使得碘化物与其他卤素离去基团的选择性碘交叉偶联具有在芳烃和烯烃基团上的官能团相容性。
• [EN] ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS<br/>[FR] ARALKYLAMINES UTILISEES EN TANT QUE MODULATEURS DES RECEPTEURS CANNABINOIDES
  申请人：MERCK & CO INC

  公开号：WO2005044785A1

  公开（公告）日：2005-05-19

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  具有结构公式(I)的新化合物是大麻素-1 (CB1)受体的拮抗剂和/或反向激动剂，在治疗、预防和抑制由CB1受体介导的疾病方面是有用的。本发明的化合物作为中枢作用药物，在治疗精神疾病、记忆缺陷、认知障碍、偏头痛、神经病、神经炎症性疾病（包括多发性硬化和吉兰-巴雷综合征）以及病毒性脑炎、脑血管意外和头部外伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症方面是有用的。这些化合物还用于治疗物质滥用障碍，包括酒精和尼古丁成瘾，治疗肥胖或饮食障碍，以及治疗哮喘、便秘、慢性假性肠梗阻和肝硬化。
• C–H arylation reactions through aniline activation catalysed by a PANI-g-C₃N₄-TiO₂ composite under visible light in aqueous medium
  作者：Liang Wang、Jun Shen、Sen Yang、Wenjie Liu、Qun Chen、Mingyang He

  DOI：10.1039/c8gc00012c

  日期：——

  composite was prepared and found to be efficient for radical C–H arylation reactions. The arylation process involved coupling of in situ generated aryl diazonium salts from aniline with heteroarenes, enol acetates or benzoquinones under visible light in aqueous medium or pure water. A broad range of substrates survived the reaction conditions to provide the desired products in moderate to good yields

  制备了聚苯胺（聚苯胺）-gC 3 N 4 -TiO 2复合材料，发现它对自由基CHH芳基化反应有效。芳基化过程涉及在水性介质或纯水中在可见光下将苯胺的原位生成的芳基重氮盐与杂芳烃，烯醇乙酸酯或苯醌结合。各种各样的底物在反应条件下均能幸存，以中等至良好的产率提供所需的产物。还实现了放大（10 mmol）合成。该半导体光催化剂显示出良好的光催化性能和稳定性。循环研究表明，这种复合材料很容易被回收，连续十次运行后，催化活性略有下降。
• [EN] SUBSTITUTED ARYL AMIDES<br/>[FR] ARYLAMIDES SUBSTITUEE
  申请人：MERCK & CO INC

  公开号：WO2003087037A1

  公开（公告）日：2003-10-23

  Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或逆向激动剂，并且在治疗、预防和抑制由CB1受体介导的疾病方面具有用途。本发明的化合物可作为精神药物用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化和吉兰-巴雷综合征）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍的治疗，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。
• [EN] SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR<br/>[FR] AMIDES SUBSTITUES ACTIFS AU NIVEAU DU RECEPTEUR DE CANNABINOIDE-1
  申请人：MERCK & CO INC

  公开号：WO2004048317A1

  公开（公告）日：2004-06-10

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或逆向激动剂，并且可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可作为中枢作用药物用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病包括多发性硬化和吉兰-巴雷综合征以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍的治疗，以及治疗哮喘、便秘、慢性肠道假性梗阻和肝硬化。